The increasing number of donations, its low cost, growing prevalence/incidence of infectious diseases, and the increasing demand for donated blood are the major factors contributing to the growth of the ELISA market.
Moreover, the high cost of NAT testing makes it unaffordable for developing economies, leaving them to rely on ELISA testing for blood screening.
The global blood screening market is broadly classified into technology, product & service, end user, and region.
Download FREE Brochure @
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267747042
The ELISA segment is projected to register the highest CAGR during the forecast period.
Target Audience for this Report:
- Blood Screening Instruments and Reagents Manufacturers
- Blood Screening Software and Services Providers
- Blood Banks
- Hospitals
- Red Cross Societies
- Regulatory Bodies
- Research and Consulting Firms
- Government Bodies
The global blood screening market is expected to reach USD 2.80 billion by 2021 from USD 1.76 billion in 2016, at a CAGR of 9.7%.
The major players in the blood screening market are Grifols (Spain), Bio-Rad Laboratories, Inc. (U.S.), Roche Diagnostics (Switzerland), bioMérieux (France), Abbott Laboratories (U.S.), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Ortho Clinical Diagnostics, Inc. (U.S.), and Becton, Dickinson and Company (U.S).
To Know More @
https://www.marketsandmarkets.com/Market-Reports/blood-screening-market-267747042.html
